title: Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
abstract: BACKGROUND
  There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375).
  
  
  METHODS
  Subjects with active AS (N=219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use: anti-TNF-naive or inadequate response/intolerance to one anti-TNF (anti-TNF-IR). The primary endpoint was Assessment of SpondyloArthritis International Society criteria (ASAS) 20 at week 16.
  
  
  RESULTS
  At week 16, 68.2% of anti-TNF-naive subjects treated with secukinumab 150 mg achieved ASAS20 compared with 31.1% treated with placebo (p<0.001). In the anti-TNF-IR group, 50.0% of subjects treated with secukinumab 150 mg achieved an ASAS20 response compared with 24.1% treated with placebo (p<0.05). Numerically greater improvements were observed with secukinumab than with placebo for most secondary endpoints. Clinical responses were sustained through week 52.
  
  
  CONCLUSIONS
  Secukinumab 150 mg provided sustained improvements in signs and symptoms of AS in anti-TNF-naive and anti-TNF-IR subjects through 52 weeks of therapy.
  
  
  BACKGROUND
  NCT01649375.
authors: Charité University Medicine Berlin, Berlin, Germany.
authors: Joachim
authors: J
authors: Sieper
authors: Oregon Health & Science University, Portland, Oregon, USA.
authors: Atul
authors: http://orcid.org/0000-0002-2130-1246
authors: A
authors: Deodhar
authors: NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust and Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
authors: Helena
authors: H
authors: Marzo-Ortega
authors: Arthritis Clinic, Jackson, Tennessee, USA.
authors: Jacob A
authors: JA
authors: Aelion
authors: Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
authors: Ricardo
authors: R
authors: Blanco
authors: Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan.
authors: Tseng
authors: T
authors: Jui-Cheng
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Mats
authors: M
authors: Andersson
authors: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
authors: Brian
authors: B
authors: Porter
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Hanno B
authors: HB
authors: Richards
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; C555450:secukinumab
keywords: Ankylosing Spondylitis; Anti-TNF; Treatment